TW200634011A - Crystalline forms of a factor xa inhibitor - Google Patents

Crystalline forms of a factor xa inhibitor

Info

Publication number
TW200634011A
TW200634011A TW094144289A TW94144289A TW200634011A TW 200634011 A TW200634011 A TW 200634011A TW 094144289 A TW094144289 A TW 094144289A TW 94144289 A TW94144289 A TW 94144289A TW 200634011 A TW200634011 A TW 200634011A
Authority
TW
Taiwan
Prior art keywords
crystalline forms
inhibitor
factor
pyridin
phenyl
Prior art date
Application number
TW094144289A
Other languages
English (en)
Chinese (zh)
Inventor
Michael J Orwat
Mary F Malley
Roxana F Schlam
Steven R Fabian
Bing-Shiou Yang
Victor W Rosso
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of TW200634011A publication Critical patent/TW200634011A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW094144289A 2004-12-15 2005-12-14 Crystalline forms of a factor xa inhibitor TW200634011A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63638704P 2004-12-15 2004-12-15
US73798505P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
TW200634011A true TW200634011A (en) 2006-10-01

Family

ID=36384503

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094144289A TW200634011A (en) 2004-12-15 2005-12-14 Crystalline forms of a factor xa inhibitor

Country Status (15)

Country Link
US (2) US7371864B2 (2)
EP (1) EP1828187A2 (2)
JP (1) JP2008524228A (2)
KR (1) KR20070087606A (2)
AR (1) AR053990A1 (2)
AU (1) AU2005317158A1 (2)
BR (1) BRPI0519331A2 (2)
CA (1) CA2589886A1 (2)
IL (1) IL183825A0 (2)
MX (1) MX2007006919A (2)
NO (1) NO20072666L (2)
PE (1) PE20060739A1 (2)
RU (1) RU2007126770A (2)
TW (1) TW200634011A (2)
WO (1) WO2006065853A2 (2)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5588970B2 (ja) 2008-05-27 2014-09-10 ダコ・デンマーク・エー／エス ハイブリダイゼーション組成物及び方法
US9303287B2 (en) * 2009-02-26 2016-04-05 Dako Denmark A/S Compositions and methods for RNA hybridization applications
US10662465B2 (en) 2011-09-30 2020-05-26 Agilent Technologies, Inc. Hybridization compositions and methods using formamide
US11118226B2 (en) 2011-10-21 2021-09-14 Agilent Technologies, Inc. Hybridization compositions and methods
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CN104744461A (zh) * 2001-09-21 2015-07-01 百时美施贵宝公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7388096B2 (en) 2004-09-28 2008-06-17 Bristol-Myers Squibb Company Crystalline forms of a factor Xa inhibitor

Also Published As

Publication number Publication date
IL183825A0 (en) 2007-09-20
KR20070087606A (ko) 2007-08-28
AU2005317158A1 (en) 2006-06-22
BRPI0519331A2 (pt) 2009-01-20
US20080188517A1 (en) 2008-08-07
JP2008524228A (ja) 2008-07-10
WO2006065853A3 (en) 2006-08-24
AR053990A1 (es) 2007-05-30
US7371864B2 (en) 2008-05-13
MX2007006919A (es) 2007-06-26
US20060148846A1 (en) 2006-07-06
PE20060739A1 (es) 2006-08-16
RU2007126770A (ru) 2009-01-27
EP1828187A2 (en) 2007-09-05
NO20072666L (no) 2007-09-07
WO2006065853A2 (en) 2006-06-22
CA2589886A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
WO2005034866A3 (en) Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors
CA2603830A1 (en) PYRIDINE [2,3-B] PYRAZINONES
WO2005023192A3 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
JO2832B1 (en) The crystals of the dihydroperidine compound are 2.1 and their production method
TW200612910A (en) Medicaments comprising carbonyl compounds, and the use thereof
WO2003062236A8 (en) 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
WO2004060313A3 (en) Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses
IL162461A0 (en) Polymorphs of clopidogrel hydrogensulfate
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2007117995A3 (en) Kinase inhibitors
WO2003082208A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
TW200624426A (en) BACE inhibitors
WO2006061417A3 (en) Macrocyclic quinazole derivatives and their use as mtki
WO2007109799A3 (en) Polymorphs of eszopiclone malate
WO2004073628A3 (en) Novel compounds
WO2005065018A3 (en) Crystalline forms of (6r) -l-erythro-tetrahydrobiopterin dihydrochloride
NO20072666L (no) Krystallinske former av en faktor Xa-inhibitor
WO2004032908A3 (en) Method of inhibiting angiogenesis
WO2008045834A3 (en) Kinase inhibitors
WO2004072029A3 (en) Pyrazolopyridazines useful as inhibitors of protein kinases
WO2005112903A3 (en) Use of ghrelin antagonists for improving cognition and memory
TW200510323A (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
UA91529C2 (en) Crystalline form of 3-(1-hydroxy-1-methyl-ethyl)-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2h-pyridin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one as a factor xa inhibitor
MX2007003426A (es) Formas cristalinas de un inhibidor del factor xa, pirazolo-[3, 4-c]-piridina.
WO2007022102A3 (en) Pentacyclic kinase inhibitors